Medpal AI PLC - Placing to raise £5m
MedPal AI plc
("MedPal AI" or the "Company")
Placing to raise
Funding to complete the acquisition of Solid State Technologies Ltd and capture the
MedPal AI Plc (AIM: MPAL, FRA: Z1N), the
The Issue Price of
In addition, the Company is issuing 10,942,857 new ordinary shares (the "Settlement Shares") in settlement of existing contractual obligations, as set out below.
Highlights
• Gross proceeds of approximately
• Proceeds fund the acquisition of Solid State Technologies Ltd ("Solid State Technologies"), a profitable electronic Medicines Administration Record ("eMAR") software business, completing MedPal's closed-loop care-home medication platform
• Positions the Company to capture the
• Strengthens working capital to support record NHS dispensing volumes and continued growth across the Company's vertically integrated platform
• Strongly supported by institutional and new investors
Use of Proceeds
The net proceeds of the Fundraise will be deployed against two highly strategic, time-sensitive and revenue-generating opportunities, alongside general working capital:
• Intended acquisition and integration of Solid State Technologies Ltd ("SST") (c.
• Oral GLP-1 launch - stock and patient acquisition (up to c.
• Working capital and growth (balance): providing operational headroom to support record NHS dispensing volumes, care home portfolio growth and general corporate purposes, including the costs of the Fundraise.
Issue of Shares in Settlement of Fees in lieu of cash
In addition to the Fundraise, the Company is issuing a total of 10,942,857 new ordinary shares of
The issue of the Settlement Shares satisfies these obligations in full without utilising the Company's cash resources. Application will be made for the Settlement Shares to be admitted to trading on AIM at the same time as the Fundraise Shares.
Details of the Fundraise
The Issue Price of
The Fundraise Shares will, when issued, rank pari passu in all respects with the existing ordinary shares of the Company, including the right to receive all dividends and other distributions declared, made or paid after their date of issue.
Application will be made to the London Stock Exchange for the Fundraise Shares and the Settlement Shares (together comprising 153,799,990 new ordinary shares) to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings in the new ordinary shares will commence at
Following Admission, the Company's issued ordinary share capital will consist of 769,841,026 ordinary shares of
The Fundraise is conditional upon, amongst other things, Admission becoming effective.
As part of OAK Securities' engagement, OAK Securities has been granted warrants to subscribe for 8,571,428 new ordinary shares, exercisable at the Issue Price for a period of 36 months from closing of the Fundraise.
Outlook
MedPal AI is entering the next phase of its growth with significant operational momentum. The current momentum of the Company's strategy has brought forward opportunities the Board had expected to address later in its plan, and growth is now being driven by three distinct and complementary engines:
• NHS pharmacy dispensing: record and rising dispensing volumes through the Company's robotic distribution hub, providing scale, cash generation and the lowest-cost fulfilment platform in the
• Care-home medication platform: the acquisition of Solid State Technologies completes the closed-loop care-home OS, converting transactional pharmacy relationships into sticky, software-led partnerships with recurring revenue; and
• Private weight-loss clinic (GLP-1): a rapidly scaling, subscription-based clinic, underpinned by direct supply relationships with Eli Lilly and Novo Nordisk, positioned to capture the
To drive the near-term marketing strategy around the launch, the Company has appointed
With the proceeds of the Fundraise, the Board believes MedPal AI is well positioned to move decisively on these opportunities and to build on the substantial momentum established over the past twelve months. The Board looks forward to updating the market on further progress over the coming weeks and months.
"Raising
"The acquisition of Solid State Technologies completes our closed-loop care-home platform - prescribe, dispense, administer and reconcile on a single system - and brings established, profitable, recurring software revenue into the Group. And with the oral Wegovy pill launching in the
"This funding gives New Health (new.co.uk), our weight-loss clinic, the firepower to compete at the highest level of the
"With three engines of growth now firing together - NHS dispensing, our care-home platform and our weight-loss clinic - and
"I would like to thank our existing shareholders for their continued support and welcome our new investors. We are moving decisively, with capital in hand, at exactly the right moment."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
Enquiries:
|
MedPal AI plc |
Via Square1 Consulting |
|
Cairn Financial Advisers LLP (Nomad) |
+44 (0) 20 7213 0880 |
|
OAK Securities (a trading name of Merlin Partners LLP) |
+44 (0) 20 3973 3678 |
|
Square1 Consulting |
+44 (0) 20 7929 5599 +44 (0) 7831 381201 |
About MedPal AI
MedPal AI is a
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms. The Company's LEI is 984500EDP8B0A14CBA61.
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE